Skip to main content

New Rhinosinusitis Guidelines Discourage Antibiotics

March 21, 2012 — New Infectious Diseases Society of America (IDSA) guidelines state that most cases of acute rhinosinusitis are caused by viruses and should not be treated with antibiotics.
According to a written release accompanying the guidelines, up to 98% of cases are caused by viruses, and therefore would not be responsive to antibiotics.
The guidelines, authored by an 11-member panel chaired by Anthony W. Chow, MD, professor emeritus of infectious diseases at the University of British Columbia, Vancouver, Canada, included contributions from experts from the US Centers for Disease Control and Prevention, the American College of Physicians, and the Society of Academic Medicine.
"There is no simple test that will easily and quickly determine whether a sinus infection is viral or bacterial, so many physicians prescribe antibiotics 'just in case,' " noted Dr. Chow in a news release. However, the use of antibiotics with viral infections may increase antibiotic resistance, costs, and the risk for adverse effects, he cautioned.
In a major shift from older guidelines developed by other organizations, the new IDSA guidelines also recommend treating bacterial sinus infections with amoxicillin-clavulanate vs amoxicillin, the current standard of care. The addition of clavulanate helps to overcome antibiotic resistance by inhibiting an enzyme that breaks the antibiotic down.
Dr. Chow notes that this recommendation was made because of increases in antibiotic resistance, as well as the widespread use of pneumococcal vaccines, which have changed the pattern of bacteria that cause sinus infections.
The guidelines also recommend against using other commonly used antibiotics, including azithromycin, clarithromycin, and trimethoprim-sulfamethoxazole, because of increasing drug resistance.
Other IDSA recommendations include shorter treatment times with antibiotics in adult patients; avoidance of decongestants and antihistamines, which may worsen symptoms; and use of irrigation with sterile solution.
The IDSA guidelines use the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system, which is designed to more clearly assess the quality of evidence and strength of recommendations.
"The guidelines are transparent, clearly stating the level of evidence for each recommendation and pointing out where we need more research," Thomas M. File Jr, MD, coauthor of the guidelines and chair of the Infectious Disease Section at Northeast Ohio Medical University, Rootstown, Ohio, noted in the news release.
Independent commentator Bradley F. Marple, MD, professor and vice chairman of the Department of Otolaryngology–Head and Neck Surgery at the University of Texas Southwestern Medical Center at Dallas, noted that these guidelines deviate significantly from the majority of existing evidence-based guidelines in their recommendations for empiric therapy for acute bacterial rhinosinusitis.
"While most national guidelines recommend the use of amoxicillin, the authors suggest a theoretic advantage for using amoxicillin-clavulanate as a first-line choice," Dr. Marple told Medscape Medical News.
"However, these concerns may not be supported by high-level clinical outcomes studies, which fail to demonstrate a clinical advantage of amoxicillin-clavulanate over amoxicillin."
According to Dr. Marple, in most guidelines, the authors rely on available high-level clinical outcome data, whereas in this case, IDSA has chosen to focus on microbiological data. "Empiric antibiotic recommendations in these guidelines are based upon 2 observations: the increasing prevalence of Haemophilus influenzae, and the increasing prevalence of beta-lactamase-producing respiratory pathogens in acute bacterial rhinosinusitis, many obtained from cultures of otitis media, which may not accurately reflect prevalence among rhinosinusitis cases overall."

Comments

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Fake drugs given to NHS patients still untraced

Only eight people out of several thousand who received counterfeit drugs from the NHS in an incident in 2007 have been identified. Of those eight, only three have been informed about the incident, a BBC investigation has learned. 72,000 packs of counterfeit drugs entered the UK supply chain in 2007 but 25,000 remain untraced. The regulator, the MHRA, has said it took swift action in 2007 and issued its "most serious recall notice". A new EU directive will further improve patient safety, it added. In the spring of 2007, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an emergency recall of drugs which had been identified as counterfeit. Those recalled included batches of the prostate cancer drug Casodex; of a drug used to treat heart complaints called Plavix; and of Zyprexa, which is used to control the symptoms of schizophrenia. The MHRA successfully seized 40,000 packs before they were distributed to pharmacies but 25,000 reached chemists acros...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...